AstraZeneca (AZN) Named One of BofA’s Top 25 Stocks for 2026

AstraZeneca PLC (NASDAQ:AZN) ranks among the Best Low Volatility Investments in December 2025. BofA Securities maintained its Buy rating on AstraZeneca PLC (NASDAQ:AZN) and increased its price target to $108.50 from $91.70 on November 25. AstraZeneca PLC (NASDAQ:AZN) was listed on the company’s Europe 1 list of top ideas and ranked as one of its 25 stocks for 2026.

Pixabay/Public Domain

According to BofA, the upcoming 12 months will see many critical clinical trial readouts with strong sales potential, including AVANZAR in NSCLC and SERENA-4 in all-comer mBC. The firm stated that, regardless of investor reservations regarding owning AstraZeneca PLC (NASDAQ:AZN) ahead of the AVANZAR readout, current consensus represents restricted peak revenue estimates, resulting in what the firm considers attractive upside potential.

Additionally, on November 21, AstraZeneca PLC (NASDAQ:AZN) announced a major $2 billion commitment to expand its manufacturing facilities in Maryland. This move will significantly boost production capacity at the Frederick biologics factory and build a new clinical manufacturing facility in Gaithersburg, creating 2,600 jobs across both locations.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.

While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.